摘要
沙库巴曲缬沙坦即血管紧张素受体脑啡肽酶抑制剂(ARNI),是近年来心力衰竭领域的研究热点。多项研究显示该药可明显降低心力衰竭患者的住院率和死亡率,并对多种心血管疾病有良好获益。本文简述了沙库巴曲缬沙坦在心力衰竭、高血压、急性心肌梗死、糖尿病、心脏代谢综合征和肾功能不全等疾病中的相关研究进展,进一步表明沙库巴曲缬沙坦现已不仅局限于射血分数降低的心力衰竭的临床应用,而是对多种心血管疾病甚至非心血管疾病均有潜在的有益作用。
Sacubitril/valsartan is angiotensin receptor enkephalinase inhibitor(ARNI)and is a research hotspot in the field of heart failure in recent years.Multiple studies have found that sacubitril/valsartan can significantly reduce the hospitalization rate and mortality of patients with heart failure,and have good benefits for a variety of cardiovascular diseases.This article briefly describes the related research progress on the effects of sacubitril/valsartan in heart failure,hypertension,acute myocardial infarction,diabetes,cardiometabolic syndrome and renal insufficiency.It further shows that sacubitril/valsartan is not limited to the clinical application of heart failure with reduced ejection fraction,but has potential beneficial effects on various cardiovascular diseases and even non-cardiovascular diseases.
作者
杨淑莲
吴晓羽
YANG Shulian;WU Xiaoyu(The First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处
《实用心脑肺血管病杂志》
2020年第5期82-86,共5页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
沙库巴曲缬沙坦
血管紧张素受体脑啡肽酶抑制剂
心力衰竭
高血压
心肌梗死
糖尿病
心脏代谢综合征
肾功能不全
Sacubitril/valsartan
Angiotensin receptor enkephalinase inhibitor
Heart failure
Hypertension
Myocardial infarction
Diabetes mellitus
Cardiometabolic syndrome
Renal insufficiency